Side-by-side comparison

ABBV vs MRK — Side-by-side comparison

MRK screens cheaper on EV/FCF, MRK has the higher ROIC, MRK has grown revenue faster over five years, and ABBV has the cleaner balance sheet by net debt / EBITDA.

ABBV

AbbVie Inc.

Price

$215.70

Market cap

$346.8B

Day %

N/A

MRK

Merck & Co.

Price

$122.41

Market cap

$208.5B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


ABBV Target	AbbVie Inc.	$346.8B	91.4x	22.8x	6.9%	6.0%	29.1%	N/A	3.7x	N/A
MRK	Merck & Co.	$208.5B	16.8x	15.7x	34.7%	9.4%	19.0%	N/A	N/A	N/A

ABBV implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

22.8x

FCF yield

5.1%

5Y rev CAGR

6.0%

MRK implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

15.7x

FCF yield

5.9%

5Y rev CAGR

9.4%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for ABBV.

Grade C

/ 100

Quality Scorecard

Build-time composite score for MRK.

Grade C

/ 100